Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

LONDON & NEW YORK, February 16, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

LONDON - Compass Pathways plc (NASDAQ:CMPS) will report new clinical data on Tuesday from its ongoing Phase 3 trials evaluating COMP360, a synthetic psilocybin formulation being studied for ...

Compass Group PLC CPG shares slid 2.62% to £21.55 Monday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.02% to 10,684.74. Compass ...

Compass Therapeutics, Inc. is set to report fourth-quarter and full-year 2025 results on Friday, with investors focused less on the biotech’s expected loss and more on progress toward a potential ...

Compass Group PLC CPG shares rose 1.35% to £21.84 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the FTSE 100 Index UKX falling 0.04% to 10,680.59. Compass ...